Eli Lilly upgrades revenue and earnings per share expectations

A new 2021 prognosis for Eli Lilly's estimated revenue and earnings per share includes several upward adjustments.

Photo: Vincent Kessler/Reuters/Ritzau Scanpix

US-based pharmaceutical giant Eli Lilly has revised its revenue and earnings per share forecasts, it announces in a press release in connection with its investment community meeting.

For 2021, Eli Lilly has upped its predicted full-year revenue to USD 28bn-28.3bn from previous estimate of USD 27.2bn-27.6bn. The analyst consensus was USD 27.58bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs